MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Molecular-genetic nature of Parkinson’s disease in the East European cohort

    A. Ivashynka, S. Likhachev (Minsk, Belarus)

    Objective: Genetic testing of the Parkin gene in patients with Parkinson's Disease (PD) in the East European cohort from Belarus. Background: The diagnosis of Juvenile…
  • 2018 International Congress

    Microarray analysis upon an synthetic α-synuclein induced model reveals some susceptibility genes in Parkinson’s disease

    E. Tao (Guangzhou, China)

    Objective: To uncover new disease-associated genes and their relevant mechanisms in the pathogenetic process of neurodegenerative disorders, we carried out a gene microarray analysis based…
  • 2018 International Congress

    Genetic variations of SNCA and striatal dopaminergic dysfunction in patients with Parkinson’s disease

    MJ. Lee, K. Pak (Busan, Korea)

    Objective: The aim of the present study was to investigate genetic variants in SNCA associated with accelerated deterioration in striatal dopaminergic activity. Background: Widespread a-synuclein…
  • 2018 International Congress

    Variants in MCCC1/LAMP3 and DGKQ Identified Through GWAS are Not Associated with PD in a Malaysian Malay Cohort

    JL. Lim, AH. Tan, SY. Lim, AA. Azlina (Kuala Lumpur, Malaysia)

    Objective: To investigate the association between variants in MCCC1/LAMP3 (rs12637471, rs12493050, rs10513789) and DGKQ (rs11248060) with PD in a Malay cohort. Background: Previous genome-wide association…
  • 2018 International Congress

    Higher Levels of Serum Uric Acid Associated with Motor & Non-Motor Symptoms in Early Parkinson’s Disease

    N. Chia, W.L. Au, Z. Lu, X. Huang, S. Ng, S. Acharyya, F. Setiawan, E. Ng, K.Y. Tay, E.K. Tan, L. Tan (Singapore, Singapore)

    Objective: Uric acid (UA) has been shown to be potentially neuroprotective in Parkinson's disease (PD), a progressive neurodegenerative disorder that is clinically characterised by motor…
  • 2018 International Congress

    MicroRNAs as Biomarkers for Parkinson’s Disease

    S. Bissonnette, C. Thomas, A. Labadorf, R. James, M. Saint-Hilaire, R. Myers (Boston, MA, USA)

    Objective: To identify potential biomarkers for Parkinson’s disease by evaluating miRNA in cerebrospinal fluid samples collected from PD and healthy control subjects. Background: The diagnosis…
  • 2018 International Congress

    Gender effects on clinical features in LRRK2 G2385R carriers and non-carriers in Parkinson’s disease

    S. Cui, S. Chen (Shanghai, People’s Republic of China)

    Objective: This study was to explore gender effects within the same genetic subtype and role of leucine-rich repeat kinase 2 (LRRK2) G2385R variants within the…
  • 2018 International Congress

    Association of GBA polymorphisms and mutations with dementia in Parkinson disease: A 7-year study of three population-based incident cohorts

    K. Lunde, J. Chung, I. Dalen, K. Pedersen, J. Linder, M. Domellöf, E. Elgh, A. Macleod, C. Tzoulis, J. Larsen, O. Tysnes, L. Forsgren, C. Counsell, G. Alves, J. Maple-Grødem (Stavanger, Norway)

    Objective: To study the effect of GBA variants on dementia in three deeply phenotyped population-based prospective cohorts of patients with incident Parkinson disease. Background: Dementia…
  • 2018 International Congress

    Genome-wide association studies of motor and cognitive progression in Parkinson’s disease

    M. Tan, L. Hubbard, M. Lawton, S. Kanavou, N. Wood, J. Hardy, Y. Ben-Shlomo, N. Williams, D. Grosset, H. Morris (London, United Kingdom)

    Objective: Motor and cognitive progression in Parkinson’s is heterogeneous. Our aim is to identify single nucleotide polymorphisms (SNPs) associated with disease progression. Background: Rare genetic…
  • 2018 International Congress

    eEF1A2 and Prdx1 as possible new targets for Parkinson’s disease therapeutics

    W. Wirakiat, P. Dharmasaroja (Bangkok, Thailand)

    Objective: We investigated expression of eEF1A2 and Prdx1 in differentiated SH-SY5Y cells in searching for possible new targets for Parkinson’s disease treatment. Background: Parkinson’s disease…
  • « Previous Page
  • 1
  • …
  • 1325
  • 1326
  • 1327
  • 1328
  • 1329
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley